Blood MicroRNA Signatures Correlate With Hippocampal Volume and Atrophy Rates

The Search for Accessible Biomarkers of Hippocampal Integrity

The clinical management of Alzheimer's disease and related dementias is increasingly shifting toward a biological definition centered on measurable biomarkers of amyloid, tau, and neurodegeneration, a classification system known as the ATN framework [1]. While hippocampal atrophy remains a hallmark of cognitive decline and a critical surrogate marker for drug efficacy, its assessment currently relies on expensive and sometimes inaccessible neuroimaging [2, 3]. Meta-analysis data indicate that pharmacological interventions can influence these structural changes, as donepezil at a 10 mg dose significantly reduces hippocampal atrophy compared to placebo (standardized mean difference = 0.44, 95% CI [0.08 to 0.81], p = 0.01) [2]. The etiology of this tissue loss is multifactorial, involving interactions between metabolic factors like glycemic control and genetics, specifically the APOE ε4 allele, which can accelerate atrophy rates by over three times in amyloid-positive individuals [4, 5]. Consequently, there is an urgent clinical need for peripheral, minimally invasive tools, such as circulating microRNAs (small non-coding RNA sequences that regulate gene expression), that can detect early pathological shifts before irreversible tissue loss occurs [6, 7]. A recent study offers fresh insights into how these circulating molecular signals in the blood may reflect deep-seated structural changes in the brain, potentially providing a more accessible way to monitor neurodegeneration.

Longitudinal Tracking of Brain Structure and Molecular Expression

The researchers utilized population-based data to investigate the relationship between molecular signals in the blood and structural brain integrity. At the study baseline, the team performed RNA sequencing (a high-throughput laboratory method used to determine the exact sequence and quantity of RNA molecules) on whole blood samples to measure the expression of microRNAs and their putative target genes. This molecular profiling was specifically designed to identify associations with left and right hippocampal volume, hippocampal asymmetry, and total brain volume, providing a comprehensive view of how circulating genetic regulators correlate with both localized and global brain structures. To track structural changes over time, the study employed 3T MRI (a high-field magnetic resonance imaging technique that provides superior tissue contrast for detailed neuroanatomy) at the initial baseline and during a follow-up period ranging from 4.60 to 8.02 years later. The researchers analyzed the resulting data using two distinct statistical frameworks to capture different temporal dynamics. For the initial cross-sectional assessment, they used linear regression to identify associations between microRNA levels and brain volumes at a single point in time. To evaluate long-term changes, they applied linear mixed-effect models (a statistical method that accounts for both fixed effects, such as age or sex, and random variations in repeated measures over time). This longitudinal approach allowed the investigators to determine how baseline microRNA expression might predict the rate of future tissue loss, offering a window into progressive neurodegeneration.

Asymmetric MicroRNA Signatures in Hippocampal Development

In the cross-sectional portion of the study, the researchers identified a distinct molecular signature in the blood that correlated specifically with the volume of the left hippocampus. Six specific microRNAs (miR-199a-3p, miR-199b-3p, miR-155-5p, miR-146a-5p, miR-6859-5p, and miR-505-5p) were associated exclusively with left hippocampal volume. This anatomical specificity is clinically significant, as these associations did not extend to the right hippocampus or total brain volume at the baseline measurement. This suggests that these circulating regulators may be tied to lateralized neurobiological processes rather than global brain changes. To determine the functional relevance of these findings, the investigators analyzed the biological pathways influenced by these six microRNAs. They found that the identified microRNAs regulated target genes involved in brain development, memory, and synapse assembly (the process by which neurons form functional connections to facilitate communication within the central nervous system). These pathways are fundamental to establishing and maintaining cognitive reserve. The data suggest that this cross-sectional microRNA signature plays an asymmetric and specialized role during the early-life development of the left hippocampus. For practicing physicians, this implies that certain blood-based markers might one day help identify baseline neurodevelopmental trajectories that ultimately influence a patient's long-term cognitive health and resilience to dementia.

Predicting Atrophy Rates Across the Aging Brain

The longitudinal portion of the study, which tracked structural changes via 3T MRI over a follow-up period of 4.60 to 8.02 years, identified a distinct set of molecular markers associated with progressive neurodegeneration. The researchers found that five specific microRNAs (miR-361-3p, miR-4473, miR-381-3p, miR-543, and miR-370-3p) were associated with atrophy rates in the left hippocampus, right hippocampus, and total brain. Unlike the cross-sectional findings that were localized to the left hippocampus, these markers appear to reflect more widespread structural decline across both hemispheres and the global cerebrum. Beyond these specific hippocampal markers, the study identified a broader molecular profile linked to global volume loss. Twenty-one microRNAs were exclusively associated with the total brain atrophy rate, suggesting that a large subset of circulating regulators specifically tracks generalized tissue loss rather than region-specific changes. To understand the biological mechanisms at play, the investigators analyzed the gene pathways influenced by these markers. They determined that the microRNAs from the longitudinal analysis regulated genes related to axonal and dendritic growth (the physiological processes by which neurons extend projections to maintain synaptic connectivity and signal transmission). These findings suggest a significant shift in the biological role of microRNAs as the brain ages. While the cross-sectional signatures appear tied to early-life development, the researchers concluded that the longitudinal signature plays a more universal role during whole-brain aging or neurodegeneration. This distinction is highly relevant for clinical diagnostics, as it separates markers of baseline structural reserve from markers of active, progressive decline. Because some of these identified microRNAs have been previously linked to dementia, they could be investigated as presymptomatic blood-based biomarkers to identify patients at risk for accelerated brain atrophy before the onset of overt clinical symptoms.

Clinical Implications for Presymptomatic Dementia Screening

The identification of specific circulating microRNAs provides a potential bridge between molecular pathology and the macroscopic brain changes observed on imaging. Several of the molecules identified in this study, particularly those associated with longitudinal atrophy rates, have been previously linked to the pathophysiology of dementia. By correlating these blood-based markers with structural changes in the hippocampus and total brain volume over a follow-up period of 4.60 to 8.02 years, the researchers have highlighted a molecular signature that tracks directly with the progression of neurodegeneration. This connection is particularly relevant for clinicians, as it suggests that the expression levels of these microRNAs reflect the underlying biological processes of axonal and dendritic growth and synapse assembly that precede clinical cognitive decline. Given the strong association between these molecular markers and the rate of tissue loss, the researchers suggest that these microRNAs could be investigated as presymptomatic blood-based biomarkers for neurodegenerative disease. In a clinical setting, such biomarkers could eventually allow physicians to identify patients at high risk for accelerated brain atrophy before the onset of overt functional impairment. Because some identified microRNAs have been previously linked to dementia, their presence in whole blood may serve as an early indicator of pathological aging. Ultimately, this could provide a critical window for earlier intervention or more intensive monitoring of hippocampal integrity, helping clinicians move beyond reactive diagnosis toward a proactive, biomarker-driven assessment of brain health.

References

1. Jack CR, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer s & Dementia. 2018. doi:10.1016/j.jalz.2018.02.018

2. Ismail YA, Haitham Y, Walid M, Mohamed H, El-Satar YMA. Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis.. BMC neurology. 2025. doi:10.1186/s12883-024-03933-4

3. Abushakra S, Doraiswamy PM, Hey JA, et al. Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.. CNS drugs. 2026. doi:10.1007/s40263-025-01251-y

4. Cai M, Lei H, Zhang Y, et al. APOE ε 4 -Associated Hippocampal Atrophy Trajectories Across the Alzheimer's Disease Continuum: A Systematic Review, Meta-Analysis, and Longitudinal Validation.. medRxiv : the preprint server for health sciences. 2025. doi:10.64898/2025.12.08.25341534

5. Pachter D, Kaplan A, Tsaban G, et al. Glycemic Control Contributes to the Neuroprotective Effects of Mediterranean and Green-Mediterranean Diets on Brain Age; The DIRECT PLUS Brain-MRI Randomized Controlled Trial.. American Journal of Clinical Nutrition. 2024. doi:10.1016/j.ajcnut.2024.09.013

6. Swarbrick S, Wragg NM, Ghosh SK, Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease. Molecular Neurobiology. 2019. doi:10.1007/s12035-019-1500-y

7. Trombetta B, Kandigian S, Williams VJ, Kivisäkk P, Carlyle B, Arnold S. P4-217: A MULTIPLE PATHOPHYSIOLOGY PANEL FOR CLINICAL TRIALS IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia. 2019. doi:10.1016/j.jalz.2019.06.3880